Supplementary Table 8A. Correlation between epigenetic clustering of patients with endometrial endometrioid cancer based on DNA methylation profile and clinicopathological parameters.

Clinicopathological parameters	Year, body mass indesx (BMI) and number of patients		P value[c]
	A (n=58)	B (n=16)	
Patients Age			
Median	49	38	8.58×10⁻³ᵈ
Interquartile range	27-77	23-50	
BMI			
Median	21.6	24.1	0.84[d]
Interquartile range	12.7-36.5	14.8-31.2	
Histological grading[a]			
G1 to G2	47	16	0.11[e]
G3	11	0	
Myometrial invasion			
Less than 1/2	40	13	0.53[e]
1/2 or more	18	3	
Lymph vessel invasion			
Absent	30	14	0.01[e]
Present	28	2	
Cervical invasion			
Absent	52	14	1.00[e]
Present	6	2	
Adnexal invasion			
Absent	52	16	0.33[e]
Present	6	0	
Lymph node metastasis			
Absent	50	15	0.67[e]
Present	8	1	
Distant metastasis			
Absent	56	16	1.00[e]
Present	2	0	
Peritoneal cytology			
Negative	54	16	0.57[e]
Positive	4	0	
The International Federation of Gynecology and Obstetorics (FIGO) stage (2008)[b]			
I to II	47	15	0.44[e]
III to IV	11	1	
Reccurence			0.57[e]
Negative	54	16	
Positive	4	0	
Outcome			1.00[e]
Alive or death of other cause	57	16	
Death of complication	1	0	

[a]Histological grading of endometrial cancer was in accordance with the Tumor-Node-Metastasis classification (Ref.25). [b]FIGO stage was defined according to Ref.26.

[c]P values of <0.05 are underlined.

[d]Mann-Whitney U test.

[e]Fisher's exact test.